Adjuvant-like Effect of Vaccinia Virus 14K Protein: A Case Study with Malaria Vaccine Based on the Circumsporozoite Protein

Development of subunit vaccines for malaria that elicit a strong, long-term memory response is an intensive area of research, with the focus on improving the immunogenicity of a circumsporozoite (CS) protein-based vaccine. In this study, we found that a chimeric protein, formed by fusing vaccinia virus protein 14K (A27) to the CS of Plasmodium yoelii, induces strong effector memory CD8+ T cell responses in addition to high-affinity Abs when used as a priming agent in the absence of any adjuvant, followed by an attenuated vaccinia virus boost expressing CS in murine models. Moreover, priming with the chimeric protein improved the magnitude and polyfunctionality of cytokine-secreting CD8+ T cells. This fusion protein formed oligomers/aggregates that led to activation of STAT-1 and IFN regulatory factor-3 in human macrophages, indicating a type I IFN response, resulting in NO, IL-12, and IL-6 induction. Furthermore, this vaccination regimen inhibited the liver stage development of the parasite, resulting in sterile protection. In summary, we propose a novel approach in designing CS based pre-erythrocytic vaccines against Plasmodium using the adjuvant-like effect of the immunogenic vaccinia virus protein 14K.

[1]  K. Marsh,et al.  Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria , 2011, PloS one.

[2]  A. Hill,et al.  CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria , 2011, The Journal of Immunology.

[3]  S. Reed,et al.  Targeting TLRs Expands the Antibody Repertoire in Response to a Malaria Vaccine , 2011, Science Translational Medicine.

[4]  A. Ghani,et al.  Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines , 2011, Proceedings of the Royal Society B: Biological Sciences.

[5]  R. Germain,et al.  Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. , 2011, The Journal of clinical investigation.

[6]  K. Marsh,et al.  Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial , 2011, The Lancet. Infectious diseases.

[7]  M. Olivier,et al.  Innate inflammatory response to the malarial pigment hemozoin. , 2010, Microbes and infection.

[8]  D. Doolan,et al.  Malaria vaccine design: immunological considerations. , 2010, Immunity.

[9]  C. Sorzano,et al.  Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions , 2010, PloS one.

[10]  R. Tyagi,et al.  Analysis of innate defences against Plasmodium falciparum in immunodeficient mice , 2010, Malaria Journal.

[11]  J. Harty,et al.  Differential Effector Pathways Regulate Memory CD8 T Cell Immunity against Plasmodium berghei versus P. yoelii Sporozoites , 2010, The Journal of Immunology.

[12]  Ueli Aebi,et al.  A Nonadjuvanted Polypeptide Nanoparticle Vaccine Confers Long-Lasting Protection against Rodent Malaria1 , 2009, The Journal of Immunology.

[13]  S. Akira,et al.  Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome , 2009, PLoS pathogens.

[14]  M. Esteban,et al.  Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. , 2009, Vaccine.

[15]  P. Schlesinger,et al.  A Novel Role for Stat1 in Phagosome Acidification and Natural Host Resistance to Intracellular Infection by Leishmania major , 2009, PLoS pathogens.

[16]  S. Kappe,et al.  Conserved Protective Mechanisms in Radiation and Genetically Attenuated uis3(-) and uis4(-) Plasmodium Sporozoites , 2009, PloS one.

[17]  M. Demoitié,et al.  Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. , 2008, The New England journal of medicine.

[18]  V. Heussler,et al.  Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid. , 2008, Vaccine.

[19]  F. Zavala,et al.  Protective CD8+ T cells against Plasmodium liver stages: immunobiology of an ‘unnatural’ immune response , 2008, Immunological reviews.

[20]  Kevin Marsh,et al.  Immunity to malaria: more questions than answers , 2008, Nature Immunology.

[21]  M. Sherman,et al.  Adjuvant potential of aggregate-forming polyglutamine domains. , 2008, Vaccine.

[22]  V. A. Stewart,et al.  Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. , 2008, Vaccine.

[23]  E. Bergmann-Leitner,et al.  C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. , 2007, Vaccine.

[24]  E. Winzeler,et al.  Plasmodium Circumsporozoite Protein Promotes the Development of the Liver Stages of the Parasite , 2007, Cell.

[25]  G. Pantaleo,et al.  Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. , 2007, Vaccine.

[26]  V. A. Stewart,et al.  Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone , 2007, Infection and Immunity.

[27]  M. Havenga,et al.  Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence. , 2007, Vaccine.

[28]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[29]  D. Webster,et al.  A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. , 2006, Vaccine.

[30]  P. Kremsner,et al.  Safety and Enhanced Immunogenicity of a Hepatitis B Core Particle Plasmodium falciparum Malaria Vaccine Formulated in Adjuvant Montanide ISA 720 in a Phase I Trial , 2005, Infection and Immunity.

[31]  S. Subbarao,et al.  Parasite killing in Plasmodium vivax malaria by nitric oxide: implication of aspartic protease inhibition. , 2004, Journal of biochemistry.

[32]  R. Sobel,et al.  Cytokine and Inducible Nitric Oxide Synthase mRNA Expression during Experimental Murine Cryptococcal Meningoencephalitis , 2004, Infection and Immunity.

[33]  G. Ciliberto,et al.  Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation , 2004, Gene Therapy.

[34]  S. Yoshida,et al.  Baculovirus virions displaying Plasmodium berghei circumsporozoite protein protect mice against malaria sporozoite infection. , 2003, Virology.

[35]  A. García-Sastre,et al.  Induction of Protective Immunity against Malaria by Priming-Boosting Immunization with Recombinant Cold-Adapted Influenza and Modified Vaccinia Ankara Viruses Expressing a CD8+-T-Cell Epitope Derived from the Circumsporozoite Protein of Plasmodium yoelii , 2003, Journal of Virology.

[36]  K. Harshman,et al.  Cellular Gene Expression Survey of Vaccinia Virus Infection of Human HeLa Cells , 2003, Journal of Virology.

[37]  M. Palmer,et al.  Expression of l-Selectin (CD62L), CD44, and CD25 on Activated Bovine T Cells , 2003, Infection and Immunity.

[38]  Danny W. Wilson,et al.  Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum , 2002, The Lancet.

[39]  S. Hoffman,et al.  Persistence of Protective Immunity to Malaria Induced by DNA Priming and Poxvirus Boosting: Characterization of Effector and Memory CD8+-T-Cell Populations , 2002, Infection and Immunity.

[40]  James M. Wilson,et al.  Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines , 2002, The Journal of experimental medicine.

[41]  M. Tsuji,et al.  Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. , 2001, International journal for parasitology.

[42]  W. Leitner,et al.  Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP‐specific Th2 type immune responses and improvesprotection against malaria infection , 2001, European journal of immunology.

[43]  J. Palensky,et al.  Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. , 2001, The Journal of infectious diseases.

[44]  Ching Li,et al.  Tumor Necrosis Factor Alpha p55 Receptor Is Important for Development of Memory Responses to Blood-Stage Malaria Infection , 2000, Infection and Immunity.

[45]  M. Esteban,et al.  Identification of Functional Domains in the 14-Kilodalton Envelope Protein (A27L) of Vaccinia Virus , 1999, Journal of Virology.

[46]  T. Daly,et al.  Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite. , 1998, Journal of immunology.

[47]  S. Hoffman,et al.  Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Marion Becker,et al.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara , 1998, Nature Medicine.

[49]  G F Gerberick,et al.  Selective modulation of T cell memory markers CD62L and CD44 on murine draining lymph node cells following allergen and irritant treatment. , 1997, Toxicology and applied pharmacology.

[50]  A. Azad,et al.  Inhibition of nitric oxide interrupts the accumulation of CD8+ T cells surrounding Plasmodium berghei-infected hepatocytes , 1997, Infection and immunity.

[51]  Joe D. Cohen,et al.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.

[52]  R A Houghten,et al.  Induction of neonatal tolerance by plasmid DNA vaccination of mice. , 1996, The Journal of clinical investigation.

[53]  S. Hoffman,et al.  Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. , 1995, Journal of immunology.

[54]  F. Liew Regulation of nitric oxide synthesis in infectious and autoimmune diseases. , 1994, Immunology letters.

[55]  B. Chait,et al.  Structural and functional properties of region II-plus of the malaria circumsporozoite protein , 1994, The Journal of experimental medicine.

[56]  P. Palese,et al.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[57]  W. Ballou,et al.  Distinct T cell specificities are induced with the authentic versus recombinant Plasmodium berghei circumsporozoite protein. , 1992, Journal of immunology.

[58]  L. Rénia,et al.  TNF inhibits malaria hepatic stages in vitro via synthesis of IL-6. , 1991, International immunology.

[59]  S. Hoffman,et al.  Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. , 1991, Journal of immunology.

[60]  T. McCutchan,et al.  Structure of the gene encoding the circumsporozoite protein of Plasmodium yoelii. A rodent model for examining antimalarial sporozoite vaccines. , 1987, The Journal of biological chemistry.

[61]  V. Nussenzweig,et al.  Circumsporozoite proteins of malaria parasites , 1985, Cell.

[62]  W. Leonard,et al.  The Jak-STAT pathway. , 2000, Molecular immunology.

[63]  R. Zinkernagel,et al.  Neutralizing antiviral B cell responses. , 1997, Annual review of immunology.

[64]  S. Hoffman,et al.  Sterile protection of monkeys against malaria after administration of interleukin-12 , 1997, Nature Medicine.